Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

Firefly Neuroscience formed a strategic partnership with NeuroSigma to introduce the FDA-cleared Monarch eTNS non-drug pediatric ADHD device to Firefly's nationwide Evoke clinician network. Monarch, indicated as monotherapy for ADHD patients aged 7-12 not taking prescription medication, began U.S. sales of its second-generation device in July 2026 after building a waitlist of more than 1,500 patients, caregivers and providers. The partnership expands potential commercial access for both Monarch and Firefly's AI-powered, FDA 510(k)-cleared EEG/ERP platform, supported by Firefly's database of more than 200,000 brain scans.

Analysis

The partnership is strategically more useful as a distribution and workflow-validation experiment than as a near-term revenue event for AIFF. Firefly appears to be providing referral/education access while NeuroSigma retains prescribing support and fulfillment, limiting AIFF's direct per-patient economics unless a disclosed referral, data, software, or testing pull-through arrangement emerges. The investable question is whether pediatric ADHD referrals increase paid Evoke utilization and create recurring longitudinal-monitoring revenue; absent that evidence, the announcement should not materially change estimates.

A second-order benefit is data generation: if clinicians use EEG/ERP assessments before and during therapy, AIFF can potentially deepen its proprietary dataset and support future biomarker validation. That value is long duration (6-18 months) and highly conditional: clinical adoption, standardized protocols, and independently validated treatment-response prediction are required before the data moat deserves a higher software/AI multiple. The immediate risk is that investors price a large pediatric-addressable-market narrative into a small-cap name before management provides network size, conversion rates, reimbursement, and revenue-share terms.

Contrarian view: restricting treatment to a narrow, medication-naive pediatric cohort may constrain throughput more than headline prevalence implies, while out-of-pocket affordability and clinician skepticism toward qEEG-guided ADHD workflows could suppress conversion. The key 1-3 month catalyst is not further partnership PR but disclosures of active Evoke sites, Monarch referrals per site, attach rate for baseline/follow-up testing, and whether any pilot outcomes translate into booked revenue. Failure to quantify these metrics by the next earnings call would support multiple compression after any news-driven rally.

Key Decisions for Investors

• No immediate directional position in AIFF solely on this release; treat as a watch-list catalyst because commercial consideration, referral economics, and the addressable clinician base are undisclosed.
• For existing AIFF longs, retain only a tactical position through the next earnings update and require evidence of paid utilization: new Evoke accounts, testing volumes, or explicit Monarch-linked revenue. Reduce on a material post-news rally without those disclosures, as the fundamental earnings impact is presently unmodelable.
• Set an earnings-call diligence trigger: add only if management quantifies a recurring revenue mechanism and demonstrates measurable testing-volume acceleration over the following quarter; falsify if adoption remains anecdotal or gross margin/operating cash burn worsens despite network expansion.
• Avoid extrapolating this into broad ADHD-drug shorts such as Takeda (TAK) or Supernus (SUPN): the eligible population and therapy positioning are too narrow to affect stimulant prescribing economics over the next 12 months.